CASI Pharmaceuticals Inc

CASI Pharmaceuticals Inc. is a biopharmaceutical company based in the United States. Founded in 1999, the company has offices in Rockville, Maryland, and Beijing, China. CASI Pharmaceuticals Inc. is dedicated to developing and delivering high-quality pharmaceutical products and innovative therapeutics to patients worldwide. The company focuses on acquiring, licensing, developing, and commercializing products that address areas of unmet medical need. CASI Pharmaceuticals Inc. has a growing product pipeline of commercially available and clinical stage drug candidates. Their portfolio includes an autologous anti-CD19 T-cell therapy investigative product (CNCT19), an anti-CD38 monoclonal antibody (CID-103), and regional rights to three FDA-approved drugs. CASI Pharmaceuticals Inc. leverages its China-based regulatory and commercial competencies and global drug development expertise to become the leading platform to launch medicines in the greater China market. Contact CASI Pharmaceuticals Inc. at their website casipharmaceuticals.com.